Payment overview · 2025
General Payments
$2,852.85
159 reported records · 27 companies
Healthcare provider profile · identity verified
Craig H Couch, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ROUND ROCK, TX · NPI 1568497733
Verified facts
What the public records show
CMS Open Payments records show Craig H Couch, M.D. received $2,852.85 in general payments during 2025 across 159 reported records.
Genentech USA, Inc. accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ubrelvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $477.08 | 16.7% | 29 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $333.32 | 11.7% | 30 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $288.22 | 10.1% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $167.52 | 5.9% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $161.12 | 5.7% | 11 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $152.33 | 5.3% | 4 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $148.76 | 5.2% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $104.62 | 3.7% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $97.32 | 3.4% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$95.74 | 3.4% | 5 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $75.52 | 2.6% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $71.96 | 2.5% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $70.31 | 2.5% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $68.88 | 2.4% | 3 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $59.96 | 2.1% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $59.93 | 2.1% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.58 | 2.0% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $55.52 | 1.9% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $41.49 | 1.4% | 2 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $39.98 | 1.4% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $39.84 | 1.4% | 2 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $39.60 | 1.4% | 2 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $34.80 | 1.2% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.24 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.64 | 1.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $27.16 | 0.9% | 1 | 2025 |
| Amicus Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.41 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,852.85 | 159 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $477.08 | 29 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $301.52 | 27 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $219.03 | 22 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $167.52 | 18 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $130.89 | 9 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $130.89 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $129.46 | 15 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $119.85 | 6 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $104.62 | 5 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $103.47 | 4 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $103.47 | 4 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $97.65 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $97.32 | 4 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $76.88 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $75.52 | 3 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $75.45 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $71.96 | 3 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $68.88 | 3 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $59.96 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $56.58 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $55.52 | 2 | 2025 |
Source payment records
|
|||||
| RYLAZE Normalized: rylaze |
Drug | JAZZ PHARMACEUTICALS INC. | $51.11 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $46.77 | 2 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $45.29 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $43.81 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $41.49 | 2 | 2025 |
Source payment records
|
|||||
| Tyruko Normalized: tyruko |
Biological | Sandoz Inc. | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $31.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.23 | 2 | 2025 |
Source payment records
|
|||||
| QALSODY Normalized: qalsody |
Drug | Biogen, Inc. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 51 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
51 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 207 | 44 |
| Memantine Hcl | Memantine Hcl | 166 | 37 |
| Sumatriptan Succinate | Sumatriptan Succinate | 163 | 35 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 161 | 25 |
| Galantamine Er | Galantamine Hbr | 152 | 26 |
| Donepezil Hcl | Donepezil Hcl | 135 | 42 |
| Aimovig Autoinjector | Erenumab-Aooe | 95 | 17 |
| Topiramate | Topiramate | 88 | 20 |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 58 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 14 |
| Ondansetron Odt | Ondansetron | 53 | 12 |
| Botox | Onabotulinumtoxina | 51 | 19 |
| Rizatriptan | Rizatriptan Benzoate | 47 | 13 |
| Emgality Pen | Galcanezumab-Gnlm | 46 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Qulipta | Atogepant | 41 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Ubrelvy | Ubrogepant | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Zolmitriptan | Zolmitriptan | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 14 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,852.85 · 159 records | Genentech USA, Inc. | AJOVY, AMVUTTRA, AMYVID, BOTOX, BRIUMVI, EPIDIOLEX, FIRDAPSE, Fintepla, KESIMPTA, KISUNLA, LEQEMBI, LUMRYZ, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONPATTRO, Ocrevus Zunovo, PANZYGA, QALSODY, QULIPTA, QUTENZA, RYLAZE, Rystiggo, SKYCLARYS, SPINRAZA, Sunosi, TRUDHESA, TYSABRI, Tyruko, UBRELVY, ULTOMIRIS, VUMERITY, VYEPTI, VYVGART HYTRULO, ZAVZPRET, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error